div class=ts-pagebuttonPage 1button div class=ts-image a href=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5page1jpg target=_blank amp-img class=ts-thumb alt=Page 1: Bebas Kesakitan · Access to palliative care assessed by morphine-equivalent consumption of strong opioid analgesics excluding Patient and family compliance srr„ P the PAN src=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5thumbnails1jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 2button div class=ts-image a href=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5page2jpg target=_blank amp-img class=ts-thumb alt=Page 2: Bebas Kesakitan · Access to palliative care assessed by morphine-equivalent consumption of strong opioid analgesics excluding Patient and family compliance srr„ P the PAN src=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5thumbnails2jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 3button div class=ts-image a href=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5page3jpg target=_blank amp-img class=ts-thumb alt=Page 3: Bebas Kesakitan · Access to palliative care assessed by morphine-equivalent consumption of strong opioid analgesics excluding Patient and family compliance srr„ P the PAN src=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5thumbnails3jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 4button div class=ts-image a href=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5page4jpg target=_blank amp-img class=ts-thumb alt=Page 4: Bebas Kesakitan · Access to palliative care assessed by morphine-equivalent consumption of strong opioid analgesics excluding Patient and family compliance srr„ P the PAN src=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5thumbnails4jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 5button div class=ts-image a href=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5page5jpg target=_blank amp-img class=ts-thumb alt=Page 5: Bebas Kesakitan · Access to palliative care assessed by morphine-equivalent consumption of strong opioid analgesics excluding Patient and family compliance srr„ P the PAN src=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5thumbnails5jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 6button div class=ts-image a href=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5page6jpg target=_blank amp-img class=ts-thumb alt=Page 6: Bebas Kesakitan · Access to palliative care assessed by morphine-equivalent consumption of strong opioid analgesics excluding Patient and family compliance srr„ P the PAN src=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5thumbnails6jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 7button div class=ts-image a href=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5page7jpg target=_blank amp-img class=ts-thumb alt=Page 7: Bebas Kesakitan · Access to palliative care assessed by morphine-equivalent consumption of strong opioid analgesics excluding Patient and family compliance srr„ P the PAN src=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5thumbnails7jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 8button div class=ts-image a href=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5page8jpg target=_blank amp-img class=ts-thumb alt=Page 8: Bebas Kesakitan · Access to palliative care assessed by morphine-equivalent consumption of strong opioid analgesics excluding Patient and family compliance srr„ P the PAN src=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5thumbnails8jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 9button div class=ts-image a href=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5page9jpg target=_blank amp-img class=ts-thumb alt=Page 9: Bebas Kesakitan · Access to palliative care assessed by morphine-equivalent consumption of strong opioid analgesics excluding Patient and family compliance srr„ P the PAN src=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5thumbnails9jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 10button div class=ts-image a href=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5page10jpg target=_blank amp-img class=ts-thumb alt=Page 10: Bebas Kesakitan · Access to palliative care assessed by morphine-equivalent consumption of strong opioid analgesics excluding Patient and family compliance srr„ P the PAN src=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5thumbnails10jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 11button div class=ts-image a href=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5page11jpg target=_blank amp-img class=ts-thumb alt=Page 11: Bebas Kesakitan · Access to palliative care assessed by morphine-equivalent consumption of strong opioid analgesics excluding Patient and family compliance srr„ P the PAN src=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5thumbnails11jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 12button div class=ts-image a href=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5page12jpg target=_blank amp-img class=ts-thumb alt=Page 12: Bebas Kesakitan · Access to palliative care assessed by morphine-equivalent consumption of strong opioid analgesics excluding Patient and family compliance srr„ P the PAN src=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5thumbnails12jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 13button div class=ts-image a href=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5page13jpg target=_blank amp-img class=ts-thumb alt=Page 13: Bebas Kesakitan · Access to palliative care assessed by morphine-equivalent consumption of strong opioid analgesics excluding Patient and family compliance srr„ P the PAN src=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5thumbnails13jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 14button div class=ts-image a href=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5page14jpg target=_blank amp-img class=ts-thumb alt=Page 14: Bebas Kesakitan · Access to palliative care assessed by morphine-equivalent consumption of strong opioid analgesics excluding Patient and family compliance srr„ P the PAN src=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5thumbnails14jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 15button div class=ts-image a href=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5page15jpg target=_blank amp-img class=ts-thumb alt=Page 15: Bebas Kesakitan · Access to palliative care assessed by morphine-equivalent consumption of strong opioid analgesics excluding Patient and family compliance srr„ P the PAN src=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5thumbnails15jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 16button div class=ts-image a href=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5page16jpg target=_blank amp-img class=ts-thumb alt=Page 16: Bebas Kesakitan · Access to palliative care assessed by morphine-equivalent consumption of strong opioid analgesics excluding Patient and family compliance srr„ P the PAN src=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5thumbnails16jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 17button div class=ts-image a href=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5page17jpg target=_blank amp-img class=ts-thumb alt=Page 17: Bebas Kesakitan · Access to palliative care assessed by morphine-equivalent consumption of strong opioid analgesics excluding Patient and family compliance srr„ P the PAN src=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5thumbnails17jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 18button div class=ts-image a href=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5page18jpg target=_blank amp-img class=ts-thumb alt=Page 18: Bebas Kesakitan · Access to palliative care assessed by morphine-equivalent consumption of strong opioid analgesics excluding Patient and family compliance srr„ P the PAN src=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5thumbnails18jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 19button div class=ts-image a href=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5page19jpg target=_blank amp-img class=ts-thumb alt=Page 19: Bebas Kesakitan · Access to palliative care assessed by morphine-equivalent consumption of strong opioid analgesics excluding Patient and family compliance srr„ P the PAN src=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5thumbnails19jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 20button div class=ts-image a href=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5page20jpg target=_blank amp-img class=ts-thumb alt=Page 20: Bebas Kesakitan · Access to palliative care assessed by morphine-equivalent consumption of strong opioid analgesics excluding Patient and family compliance srr„ P the PAN src=https:reader030vdocumentinreader030viewer20220315075c97543009d3f2060a8bf05fhtml5thumbnails20jpg width=142 height=106 layout=responsive amp-imga divdiv